$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000143774923007531 Filed on March 22, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.590M	$3.152M	$12.61M
YoY Change	10.5%	5.03%	11.47%
% of Gross Profit
Research & Development	$3.508M	$4.986M	$15.08M
YoY Change	134.02%	172.95%	63.77%
% of Gross Profit
Depreciation & Amortization	$3.000K	$2.000K	$8.000K
YoY Change	50.0%	15.61%	-65.22%
% of Gross Profit
Operating Expenses	$7.098M	$8.138M	$27.69M
YoY Change	49.53%	68.56%	34.94%
Operating Profit	-$7.098M		-$27.69M
YoY Change	49.53%		34.94%
Interest Expense	$821.0K	$869.0K	$755.0K
YoY Change	-2931.03%
% of Operating Profit
Other Income/Expense, Net	-$33.00K	-$222.0K	-$146.0K
YoY Change	-15.38%	6015.7%	71.76%
Pretax Income	-$6.281M	-$7.491M	-$26.96M
YoY Change	31.24%	55.04%	30.84%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$6.281M	-$7.491M	-$26.96M
YoY Change	31.26%	55.04%	30.84%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.05		-$0.21
Diluted Earnings Per Share	-$0.05	-$0.06	-$0.21
COMMON SHARES
Basic Shares Outstanding	126.6M	126.6M	126.6M
Diluted Shares Outstanding	126.6M		126.6M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.9M	$110.9M	$110.9M
YoY Change	-21.0%	-18.69%	-18.69%
Cash & Equivalents	$103.9M	$110.9M	$110.9M
Short-Term Investments
Other Short-Term Assets	$858.0K	$2.423M	$6.564M
YoY Change	20.85%	103.1%	73.15%
Inventory
Prepaid Expenses	$5.295M	$4.031M
Receivables
Other Receivables
Total Short-Term Assets	$110.9M	$118.2M	$118.2M
YoY Change	-18.98%	-16.31%	-16.31%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$4.700M	$4.700M	$4.700M
YoY Change
Other Assets	$631.0K	$635.0K	$635.0K
YoY Change	0.16%	2786.36%	31650.0%
Total Long-Term Assets	$5.331M	$5.335M	$5.335M
YoY Change	746.19%	24150.0%	24150.0%
TOTAL ASSETS
Total Short-Term Assets	$110.9M	$118.2M	$118.2M
Total Long-Term Assets	$5.331M	$5.335M	$5.335M
Total Assets	$116.2M	$123.5M	$123.5M
YoY Change	-15.48%	-12.55%	-12.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.444M	$2.965M	$2.965M
YoY Change	-9.52%	72.68%	72.68%
Accrued Expenses	$613.0K	$1.059M	$2.584M
YoY Change	410.83%	419.12%	86.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.944M	$5.568M	$5.568M
YoY Change	26.79%	78.12%	78.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.944M	$5.568M	$5.568M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.944M	$5.568M	$5.568M
YoY Change	26.79%	78.12%	78.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$162.5M	-$156.2M
YoY Change	21.23%	20.86%
Common Stock	$275.1M	$273.6M
YoY Change	2.44%	2.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$113.3M	$118.0M	$118.0M
YoY Change
Total Liabilities & Shareholders Equity	$116.2M	$123.5M	$123.5M
YoY Change	-15.48%	-12.55%	-12.55%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$6.281M	-$7.491M	-$26.96M
YoY Change	31.26%	55.04%	30.84%
Depreciation, Depletion And Amortization	$3.000K	$2.000K	$8.000K
YoY Change	50.0%	15.61%	-65.22%
Cash From Operating Activities	-$7.022M	-$4.523M	-$20.76M
YoY Change	43.95%	23.4%	26.03%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$8.000K	$27.00K
YoY Change	-100.0%	1900.0%	200.0%
Acquisitions
YoY Change
Other Investing Activities		-$2.000M	-$4.700M
YoY Change
Cash From Investing Activities	$0.00	-$2.008M	-$4.727M
YoY Change	-100.0%	-502100.0%	52422.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	$0.00
YoY Change		-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-$7.022M	-4.523M	-$20.76M
Cash From Investing Activities	$0.00	-2.008M	-$4.727M
Cash From Financing Activities	$0.00	0.000	$0.00
Net Change In Cash	-$7.022M	-6.531M	-$25.49M
YoY Change	43.57%	78.23%	-126.32%
FREE CASH FLOW
Cash From Operating Activities	-$7.022M	-$4.523M	-$20.76M
Capital Expenditures	$0.00	$8.000K	$27.00K
Free Cash Flow	-$7.022M	-$4.531M	-$20.79M
YoY Change	43.57%	23.6%	26.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126624000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126624000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126624000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126624000
CY2021	atos	Issuance Of Common Stock And Warrants Issuance Costs IssuanceOfCommonStockAndWarrantsIssuanceCosts	5493	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000	usd
CY2022	atos	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	200000
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35610
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-4753208
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	107 Spring Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Seattle
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98104
CY2022	dei	City Area Code CityAreaCode	206
CY2022	dei	Local Phone Number LocalPhoneNumber	588-0256
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.18 par value
CY2022	dei	Trading Symbol TradingSymbol	ATOS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	137982260	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	126624110
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2022	dei	Auditor Name AuditorName	BDO USA, LLP
CY2022	dei	Auditor Location AuditorLocation	Seattle, Washington
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110890000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136377000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	110000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	110000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4031000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2488000	usd
CY2022Q4	atos	Research And Development Tax Rebate Receivable ResearchAndDevelopmentTaxRebateReceivable	743000	usd
CY2021Q4	atos	Research And Development Tax Rebate Receivable ResearchAndDevelopmentTaxRebateReceivable	1072000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2423000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1193000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	118197000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	141240000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	4700000	usd
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	0	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	635000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22000	usd
CY2022Q4	us-gaap	Assets Assets	123532000	usd
CY2021Q4	us-gaap	Assets Assets	141262000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2965000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1717000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1059000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	204000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1525000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1184000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	19000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	21000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5568000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3126000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5568000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3126000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22792000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	22792000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	250784000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	243996000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-156194000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129234000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	117964000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	138136000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123532000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141262000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15083000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9210000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12608000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11311000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	27691000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	20521000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-27691000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-20521000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	877000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-146000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-91000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26960000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20606000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26960000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126624000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116950000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	27168000	usd
CY2021	atos	Common Stock And Warrants Issued During Period Value New Issues CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues	69668000	usd
CY2021	atos	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	43818000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1724000	usd
CY2021	atos	Stock Repurchased During Period For Stock Option Exercise And Taxes Value StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue	-1906000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5267000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	138136000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6788000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26960000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	117964000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26960000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	6788000	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	5267000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23000	usd
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-3000	usd
CY2021	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-0	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1543000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	674000	usd
CY2022	atos	Increase Decrease In Research And Development Tax Rebate Receivable IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable	-329000	usd
CY2021	atos	Increase Decrease In Research And Development Tax Rebate Receivable IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable	437000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1230000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	521000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	597000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-0	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1248000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	128000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	855000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	111000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	341000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	220000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	17000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20760000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16472000	usd
CY2022	atos	Payments To Acquire Equity Securities Without Readily Determinable Fair Value PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue	4700000	usd
CY2021	atos	Payments To Acquire Equity Securities Without Readily Determinable Fair Value PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue	-0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4727000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	usd
CY2022	atos	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	0	usd
CY2021	atos	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	69668000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	43818000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	391000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	-0	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	573000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	113304000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25487000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	96823000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	136487000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39664000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	111000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	136487000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110890000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136377000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	111000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	136487000	usd
CY2022	atos	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	0	usd
CY2021	atos	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	13003000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	1333000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"><b><a href="#" id="notes" title="notes"/>NOTE <em style="font: inherit;">1:</em> NATURE OF OPERATIONS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:72pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 14.4pt 0pt 5.2pt; text-align: left; text-indent: 54pt;">Atossa Therapeutics, Inc. (the Company) was incorporated on <em style="font: inherit;"> April 30, 2009, </em>in the State of Delaware to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is currently focused on developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and other breast conditions. The Company's fiscal year ends on <em style="font: inherit;"> December 31.</em></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 14.4pt 0pt 5.2pt; text-align: left; text-indent: 54pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 54pt;"><b><i>Impact of the Ongoing Coronavirus Pandemic </i> </b></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt; text-indent: 54pt;">The ongoing COVID-<em style="font: inherit;">19</em> pandemic <em style="font: inherit;"> may </em>affect the Company’s operations and those of <em style="font: inherit;">third</em>-parties on which the Company relies, including causing possible disruptions in the supply of the Company’s (Z)-endoxifen, AT-<em style="font: inherit;">H201</em> and the pace of enrollment in the Company’s clinical trials. In addition, the COVID-<em style="font: inherit;">19</em> pandemic <em style="font: inherit;"> may </em>affect the operations of the U.S. FDA and other health authorities, including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. As the COVID-<em style="font: inherit;">19</em> pandemic reaches endemic stages, the extent to which it <em style="font: inherit;"> may </em>continue to impact the Company’s operations, including COVID-<em style="font: inherit;">19</em>-related delays or other impacts on the Company’s business, financing or clinical trial activities or on healthcare systems or the global economy as a whole, remains highly uncertain and difficult to predict; however, the Company has <em style="font: inherit;">not</em> experienced a significant delay in the enrollment or the drug supply for its ongoing and planned clinical studies, including studies of (Z)-endoxifen and AT-<em style="font: inherit;">H201.</em> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 14.4pt 0pt -4pt; text-align: left; text-indent: 54pt;"><i> </i></p>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26960000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20760000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110890000	usd
CY2022Q4	atos	Working Capital Deficit WorkingCapitalDeficit	112629000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 54pt;"><b><i>Reclassification</i></b></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 54pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 54pt;">Interest income has been reclassified from prior period amounts to conform to the current year presentation.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 54pt;"> </p>
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 54pt;"><i><b>Use of Estimates</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 54pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2021	atos	Stock Issued During Period Shares Warrant Exercised StockIssuedDuringPeriodSharesWarrantExercised	37451000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	atos	Research And Development Current ResearchAndDevelopmentCurrent	3480000	usd
CY2021Q4	atos	Research And Development Current ResearchAndDevelopmentCurrent	1853000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	387000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	461000	usd
CY2022Q4	atos	Professional Services Current ProfessionalServicesCurrent	130000	usd
CY2021Q4	atos	Professional Services Current ProfessionalServicesCurrent	124000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	0	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	14000	usd
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	0	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	5000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	34000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	31000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4031000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2488000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1060000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	894000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	224000	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	183000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	241000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	107000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1525000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1184000	usd
CY2022Q4	atos	Number Of Shares Authorized To Issue NumberOfSharesAuthorizedToIssue	185000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	atos	Stockholder Rights Agreement Number Of Preferred Stock Right Distributed For Each Share Of Common Stock StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock	1
CY2014Q2	atos	Stockholder Rights Agreement Acquiring Person Percentage Of Ownership StockholderRightsAgreementAcquiringPersonPercentageOfOwnership	0.15	pure
CY2014Q2	atos	Stockholder Rights Agreement Acquiring Person Additional Percentage Of Ownership StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership	0.020	pure
CY2014Q2	atos	Stockholder Rights Agreement Initial Exercise Price Of Each Right StockholderRightsAgreementInitialExercisePriceOfEachRight	15.00
CY2014Q2	atos	Stockholder Rights Agreement Share Price StockholderRightsAgreementSharePrice	30.00
CY2022Q4	atos	Consummate A Business Combination Percentage Of Acquired Outstanding Shares ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares	0.50	pure
CY2022Q4	atos	Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower	0.50	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21515
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21515
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	43818000	usd
CY2021	atos	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	37451000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26960000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126624000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116950000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	34981000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33351000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5662000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4327000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	351000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	0	usd
CY2022	atos	Effective Income Tax Rate Reconciliation Nontaxable Rd Rebate Amount EffectiveIncomeTaxRateReconciliationNontaxableRdRebateAmount	156000	usd
CY2021	atos	Effective Income Tax Rate Reconciliation Nontaxable Rd Rebate Amount EffectiveIncomeTaxRateReconciliationNontaxableRdRebateAmount	-0	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	214000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	81000	usd
CY2022	atos	Effective Income Tax Rate Reconciliation Other Deferred Items EffectiveIncomeTaxRateReconciliationOtherDeferredItems	862000	usd
CY2021	atos	Effective Income Tax Rate Reconciliation Other Deferred Items EffectiveIncomeTaxRateReconciliationOtherDeferredItems	-100000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	213000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
CY2022	atos	Effective Income Tax Rate Reconciliation Dual Taxation On Foreign Subsidiary Amount EffectiveIncomeTaxRateReconciliationDualTaxationOnForeignSubsidiaryAmount	270000	usd
CY2021	atos	Effective Income Tax Rate Reconciliation Dual Taxation On Foreign Subsidiary Amount EffectiveIncomeTaxRateReconciliationDualTaxationOnForeignSubsidiaryAmount	-0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	27000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-557000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4421000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4903000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	222000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	47000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	38000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4067000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3007000	usd
CY2022Q4	atos	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	3155000	usd
CY2021Q4	atos	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	315000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	382000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11522000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11511000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19327000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14937000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	atos	Gross Net Operating Loss Carryforwards GrossNetOperatingLossCarryforwards	52700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19327000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14937000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4390000	usd
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4903000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	110647000	usd
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	136185000	usd
CY2022Q1	atos	Lessee Operating Lease Monthly Rent Payments LesseeOperatingLeaseMonthlyRentPayments	1000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	15000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	26000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6788000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5267000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10027000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.82
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4079000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.13
CY2022	atos	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	51000	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.91
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13906000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.35
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M25D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10283000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.59
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13906000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.35
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M25D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3623000

Files In Submission

Name	View Source	Status
0001437749-23-007531-index-headers.html	Edgar Link	pending
0001437749-23-007531-index.html	Edgar Link	pending
0001437749-23-007531.txt	Edgar Link	pending
0001437749-23-007531-xbrl.zip	Edgar Link	pending
atos-20221231.xsd	Edgar Link	pending
atos-20221231_cal.xml	Edgar Link	unprocessable
atos20221231_10k.htm	Edgar Link	pending
cdp01.jpg	Edgar Link	pending
ex_455745.htm	Edgar Link	pending
ex_455746.htm	Edgar Link	pending
ex_455747.htm	Edgar Link	pending
ex_455748.htm	Edgar Link	pending
ex_455749.htm	Edgar Link	pending
ex_455750.htm	Edgar Link	pending
ex_488409.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
atos-20221231_def.xml	Edgar Link	unprocessable
atos-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
atos-20221231_pre.xml	Edgar Link	unprocessable
atos20221231_10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2023 Q1 Form 10-K Financial Statement

#000143774923007531 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2023 Q1 Form 10-K Financial Statement

#000143774923007531 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos